SZShukhrat Khudaiberdievich Ziyadullaev

Shukhrat Khudaiberdievich Ziyadullaev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shukhrat Khudaiberdievich Ziyadullaev has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immunomodulatory effect of intravenous immunoglobulin in patients with inflammatory dilated cardiomyopathy

    by Sh.KH. Ziyadullaev, A.A. Rakhmatullaev, T.U. Aripova, A.A. Ismailova, Kh.M. Khatamov, Sh.SH. Khudoyberdiev

  • Open Access

    The experience of using omalizumab biosimilar in patients with atopic bronchial asthma and clinically significant sensitization to aeroallergens in the Republic of Uzbekistan

    by T.U. Aripova, Z.S. Kamalov, Sh.KH. Ziyadullaev, N.D. Dustbabaeva, V.F. Baybekova, N.P. Aydarova

    Опыт применения биоаналога омализумаба у пациентов с атопической бронхиальной астмой и клинически значимой сенсибилизацией к аэроаллергенам в

  • Open Access

    Synovial Fluid as a Crucial Component of the Joint Microenvironment in Rheumatoid Arthritis

    by Shukhrat Khudaiberdievich Ziyadullaev, Shavkat Shukhratovich Khudaiberdiev, Tamara Uktamovna Aripova, Salvatore Chirumbolo, Zaynitdin Saifitdinovich Kamalov, Geir Bjørklund, Jasur Alimdjanovich Rizaev, Eleonora Negmatovna Tashkenbaeva, Obid Abdurakhmanovich Khamidov, Usmon Bobonazarovich Gaffarov

    Ziyadullaev SK, et al. Immune Netw. 2025 Feb;25(2):e2. https://doi.org/10.4110/in.2025.25.e2


  • Neuropathic component of pain, comorbidity and quality of life in rheumathoid arthritis: are there any relationships?

    by N.M. Nikitina, E.V. Egorova, L.R. Bogdalova, Sh.KH. Ziyadullaev, A.P. Rebrov

    The quality of life (QL) of patients with rheumatoid arthritis (RA) is associated not only with the disease activity, but also with the presence and severity of pain, as well as with comorbidity. Objective. To determine the nature of pain syndrome in patients with RA and the role of neuropathic component of pain (NCP) in identifying the QL of patients with RA and comorbidity. Material and methods. The study included 163 women with confirmed RA (mean age 53.9±10.2 years, median RA duration 10 [4; 14] years), with moderate and high RA activity (DAS28: 5.2 [4.4; 5.8]). The clinical and laboratory examinations, QL assessment with the use of HAQ and EQ-5D questionnaires and pain evaluation using visual analogue scale were conducted. NCP was identified by means of the DN4 questionnaire. The Charlson, Kaplan-Feinstein and CIRS indices were used to assess the comorbid status of patient. The severity of anxiety and depression was determined by the Hospital Anxiety and Depression Scale (HADS). Results. The presence of NCP has been found in 49.7% of RA patients. When NCP joined, the DAS28 indicator of RA activity became less informative for evaluating the efficacy of therapy in patients with RA. Patients with NCP had significantly higher anxiety/depression level than patients without this component of pain. The higher Charlson, CIRS and Kaplan-Feinstein indices were revealed in patients with NCP. QL in RA patients was worse when the pain was combined with a neuropathic component. Conclusion. Patients with RA have a mixed type of pain. The presence of NCP makes it difficult to assess RA activity. The relationships between the character of pain, anxiety-depressive disorders and comorbidity and QL indices of patients with RA have been found. Preliminary determination of the patient’s pain phenotype before treatment can lead to a better response on it through a personalized approach to therapy.

  • The effectiveness of therapy and the quality of life of patients with rheumatoid arthritis depending on the baseline treatment adherence

    by N.M. Nikitina, E.V. Egorova, L.R. Bogdalova, Sh.KH. Ziyadullaev, A.P. Rebrov

    Treatment adherence is an essential component of the effectiveness of therapy and the preservation of a good quality of life. Objective. To evaluate the real-world effectiveness of therapy and quality of life (QoL) of patients with rheumatoid arthritis (RA) after one year of follow-up, depending on baseline compliance. Material and methods. The study included 132 females with confirmed RA (age 55.5±10.5 years, duration of RA 10.2 [4; 14] years), with moderate and high activity of RA (DAS 28 score of 5.0 [4.3; 5.8]). Clinical and laboratory examination was conducted: QoL assessment using HAQ questionnaire and EQ-5D. Pain was assessed on a visual analog scale (VAS), treatment adherence was evaluated using the questionnaire for qualitative assessment of adherence to Morisky-Green and the QAA-25 — questionnaire for quantitative assessment of adherence (according to N.A. Nikolaev). In 60 patients comparable in baseline characteristics of the disease with different levels of adherence, the examinations were carried out at baseline and after a year. Results. Low treatment adherence was shown by the Morisky-Green questionnaire in 68 (52.3%) of 132 and by the QAA-25 questionnaire in 33 (40.3%) of 82 females with RA. The least adherence to the recommendations for lifestyle modification was noted. Predictors of high treatment adherence were the young age of patients, a shorter duration of the disease, and a lower level of pain according to VAS. In patients with RA with initially low adherence to treatment after a year, an increase in the disease activity and a decrease in quality of life were noted, despite the therapy. Conclusion. The relationships we have identified between baseline adherence, disease activity, and quality of life after one year of follow-up demonstrate the importance of considering baseline adherence. The least adherence was to lifestyle changes. Further research is needed on the factors affecting overall adherence and its components. The development of methods to increase treatment adherence can improve the effectiveness of therapy and the quality of life of patients with rheumatoid arthritis.

  • Open Access

    Immune changes in synovial fluid in rheumatoid arthritis

    by Sh.Kh. Ziyadullaev, Samarkand State Medical University of the Ministry of Health of the Republic of Uzbekistan, Sh.Sh. Khudaiberdiev, T.U. Aripova, Ja.A. Rizaev, Z.S. Kamalov, I.I. Sultonov, B.B. Pardaev, A.A. Kim, Samarkand Branch of the Republican Specialized Scientifi c and Practical Medical Center of Traumatology and Orthopedics of the Ministry of Health of the Republic of Uzbekistan

    Иммунные изменения в синовиальной жидкости при ревматоидном артрите


  • CLINICAL CASE FROM RHEUMATOLOGICAL PRACTICE: COMPLICATION OF SYSTEMIC SCLERODERMIA

    by L.KH. Tashinova, Sh.KH. Ziyadullaev

    A systemic disease of the connective tissue, characterized by progressive fibrosis of the skin and internal organs (leading to their failure), disorders of the morphology and function of blood vessels, and disorders of the immune system. Systemic scleroderma (SSD) is characterized by a severe course with high activity, multiple organ damage due to systemic damage and an unfavorable prognosis.


  • Immunostimulating therapy in treatment of Community-acquired pneumonia

    by Feruz Ahmedov, Nematilla Aralov, Shukhrat Ziyadullaev, Mirgolib Rakhimov

    Constantly developing antibiotic resistance of microorganisms and immunological aspects of pathogenesis of pneumonia requires the need for rational antibiotic therapy, taking into account features of the immunological response of the organism. To study the role of immunostimulatory therapy with polyoxidonium in combination therapy based on immunological monitoring of patients with community-acquired pneumonia. The study involved 47 patients who received hospital treatment according to clinical and radiological data diagnosed with community-acquired pneumonia of varying severity. To evaluate the severity in patients with community-acquired pneumonia was used scale Pneumonia PORT. Determination of lymphocyte immunophenotype, and the level of humoral immunity parameters Ig classes A, M, G. It was found that in the studied group of patients with community-acquired pneumonia occur expressed disturbances of the immune status, manifested deficiency of cellular CD3+, CD4+, CD16+, B-lymphopenia and disimmunoglobulinemiya against the background of systemic inflammatory response. After applying polyoxidonium in patients with community-acquired pneumonia marked improvement in immune status. So, a significant increase in CD3+, CD4+, CD16+ cells compared to original data, normalization level CD19+ and elevated serum levels of IgA, IgG and IgM. Thus, the inclusion in the complex therapy of patients with community-acquired pneumonia polyoxidonium accompanied by rapid relief of inflammation and intoxication syndromes, reduced signs of damage lung tissue, normalizing the immune status.

  • LBPS 02-51 ROLE OF THE SYSTEM METALLOPROTEINASE AND THEIR INHIBITORS AT A HEART FAILURE

    by Shukhrat Ziyadullaev, Gavhar Dushanova, Gulchehra Ahmedova

    To study the level of activity of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-4 (TIMP-4) at different classes of heart failure. The study included 38 patients who were on treatment for heart failure. The diagnosis of heart failure was established based on the NYHA classification. The presence of heart failure confirmed by echocardiography with assessment of systolic and diastolic left ventricular (LV) function. In all patients at admission was determined in the serum levels of MMP-9 and TIMP-4 by ELISA using laboratory kits BCM Diagnostics (USA). Thus, the concentration of MMP-9 in the serum of patients with heart failure I, II and III class was increased as compared with the control subjects and averaged 4.51 ± 0.27 ng/ml. The concentration of TIMP-4 in the serum of patients with heart failure I, II and III class was reduced as compared with the control subjects and averaged 0.26 ± 0.04 ng/ml. Concentration in blood of MMP-9 for patients with class II heart failure was 12% higher than the class I, and class III at - 24% higher than on class II heart failure. The concentration of TIMP-4 in patients with class II was 14% lower than the class I, and class III at - 25% lower than class II heart failure. The results of this work have established a pattern of participation of MMP-9 and TIMP-4 in the processes that accompany the restructuring of the extracellular matrix of the heart during remodeling LV, development and progression of heart failure. Therefore, the further task will be to search for drugs and the development of new approaches to the treatment of heart failure from the point of view of the study of pathogenetic mechanisms.